Status:
COMPLETED
A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable Rheumatoid Arthritis Patients in Clinical Remission
Lead Sponsor:
AbbVie (prior sponsor, Abbott)
Collaborating Sponsors:
Pharma Consulting Group AB
Conditions:
Arthritis, Rheumatoid
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this pilot study is to investigate the possibility of discontinuing adalimumab therapy in patients with rheumatoid arthritis who are in stable remission after treatment with adalimumab ...
Detailed Description
Treatments with adalimumab and other tumor necrosis factor (TNF) blockers, once started as therapy for rheumatoid arthritis (RA), are usually continued indefinitely. Information concerning the possibi...
Eligibility Criteria
Inclusion
- Age ≥18 years.
- Diagnosis of RA as defined by the 1987-revised American College of Rheumatology (ACR)-classification and has positive rheumatoid factor (RF) test or erosion on X-ray of hands or feet.
- Currently treated with adalimumab and MTX (at least 10 mg/week; orally or subcutaneously).
- In remission as defined by disease activity score (DAS)28 \<2.6 for at least the past 3 months.
- Concomitant disease-modifying anti-rheumatic drug (DMARD) or oral corticosteroid therapy has been stable for at least 3 months at study entry.
- Female subject is either not of childbearing potential or is practicing a relevant method of birth control.
- Subject is judged to be in good general health.
- Subjects must be able and willing to provide written informed consent.
- Subjects must be able and willing to self-administer subcutaneous (SC) injections or have a qualified person available to administer SC injections.
Exclusion
- Treatment with intra-articular or parenteral administration of corticosteroids in the preceding 4 weeks.
- Oral prednisone or prednisone equivalent \> 10 mg/day at baseline.
- Joint surgery within the preceding two months.
- History of acute inflammatory joint disease other than RA.
- Treatment with any investigational drug within 30 days or 5 half lives, whichever is longer prior to study entry.
- Poorly controlled medical condition, which would put the subject at risk by participation in the study.
- History of clinically significant hematologic, renal or liver disease.
- Diagnosis of, or history suggestive of, central nervous system (CNS) demyelinating disease.
- History of cancer or lymphoproliferative disease other than a successfully treated non-metastatic cutaneous squamous cell or basal cell carcinoma or localized carcinoma of the cervix.
- History of listeriosis, histoplasmosis, untreated tuberculosis (TB), persistent chronic infections, or recent active infections.
- Known immune deficiency or human immunodeficiency virus (HIV).
- Female who is pregnant or breast-feeding or considering becoming pregnant or breast feeding during the study.
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2012
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT00808509
Start Date
January 1 2009
End Date
September 1 2012
Last Update
December 16 2013
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Site Reference ID/Investigator# 22062
Linköping, Sweden, 581 85
2
Site Reference ID/Investigator# 14022
Lund, Sweden, 22185
3
Site Reference ID/Investigator# 14023
Malmo, Sweden, 20502
4
Site Reference ID/Investigator# 14301
Oskarström, Sweden, 31392